Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Jumped Today

By Joe Tenebruso – Nov 19, 2021 at 6:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Booster shots could soon be available for all U.S. adults.

What happened

Shares of Moderna (MRNA -1.72%) climbed 5% on Friday after U.S. health regulators took steps toward making COVID-19 booster vaccines available for more Americans. 

So what

The U.S. Food and Drug Administration (FDA) authorized booster shots developed by Moderna and rival drugmaker Pfizer for people aged 18 and older. The shots are designed to be administered at least six months after people receive their second dose.

"Throughout the course of the COVID-19 pandemic, the FDA has worked to make timely public health decisions as the pandemic evolves," acting FDA commissioner Janet Woodcock said in a press release. "Vaccines have proven to be the best and highly effective defense against COVID-19."

A healthcare professional is administering a vaccine.

Image source: Getty Images.

Woodcock said booster shots will offer better protection against the most serious potential effects of the disease, including hospitalization and death. Health officials also said that expanding the eligibility criteria to all U.S. adults would help reduce confusion about who could get one. The FDA had previously authorized booster shots for people 65 years of age and older, younger individuals who were at high risk of severe COVID-19, and adults with "frequent institutional or occupational exposure" to the novel coronavirus.

Now what 

Shortly before the market close, an advisory committee for the Centers for Disease Control and Prevention (CDC) voted in favor of booster shots. CDC Director Rochelle Walensky is now expected to sign off on the additional vaccine doses in short order. 

That would pave the way for Moderna to begin supplying doses to tens of millions of Americans who received their primary series of its COVID-19 vaccine earlier this year.

"This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country," Moderna CEO Stéphane Bancel said. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.